Dr. Steven Coutre on Frontline Treatment Decisions in CLL

​Steven Coutre, MD
Published: Saturday, Oct 01, 2016


Steven Coutre, MD, professor of medicine (hematology) at Stanford University Medical Center, discusses considerations when selecting between oral therapies like ibrutinib and chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia (CLL).
 
When determining frontline treatment, it is important to consider each patient’s individual needs, and not just make a medical-based decision, says Coutre.
 
A frail patient or a patient with multiple comorbidities may not be able to tolerate a chemoimmunotherapy regimen, and should therefore be given an oral regimen.
 
Financial constraints may also need to be a considered for some patients. A defined course of therapy like chemoimmunotherapy may be fully reimbursed by insurance, while a long-term oral therapy may not be, says Coutre.

<<< View more from the 2016 NCCN Hematologic Malignancies Congress


Steven Coutre, MD, professor of medicine (hematology) at Stanford University Medical Center, discusses considerations when selecting between oral therapies like ibrutinib and chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia (CLL).
 
When determining frontline treatment, it is important to consider each patient’s individual needs, and not just make a medical-based decision, says Coutre.
 
A frail patient or a patient with multiple comorbidities may not be able to tolerate a chemoimmunotherapy regimen, and should therefore be given an oral regimen.
 
Financial constraints may also need to be a considered for some patients. A defined course of therapy like chemoimmunotherapy may be fully reimbursed by insurance, while a long-term oral therapy may not be, says Coutre.

<<< View more from the 2016 NCCN Hematologic Malignancies Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x